Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Hematopoietic Stem Cells in ALS
NCT01933321Phase 3Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Sep 2012
- Primary completion
- Jan 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous hematopoietic stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: Evaluation of autologous intrathecal administration of hematopoietic stem cells at 12 months. Started Sep 2012; status: completed.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01933321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933321.